Apyx Medical Corporation (APYX)
| Market Cap | 118.37M -28.5% |
| Revenue (ttm) | 59.57M +24.4% |
| Net Income | -8.44M |
| EPS | -0.19 |
| Shares Out | 42.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 43,008 |
| Open | 2.850 |
| Previous Close | 2.890 |
| Day's Range | 2.650 - 2.850 |
| 52-Week Range | 2.250 - 5.080 |
| Beta | 1.46 |
| Analysts | Strong Buy |
| Price Target | 6.50 (+131.32%) |
| Earnings Date | Nov 5, 2026 |
About APYX
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparo... [Read more]
Financial Performance
In 2025, Apyx Medical's revenue was $52.84 million, an increase of 9.86% compared to the previous year's $48.10 million. Losses were -$11.21 million, -52.22% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for APYX stock is "Strong Buy." The 12-month stock price target is $6.5, which is an increase of 131.32% from the latest price.
News
Apyx Medical Transcript: Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum
GLP-1-driven weight loss is expanding demand for surgical body contouring and skin tightening. AYON is now complete in the U.S., while 2026 guidance calls for $59M-$60M revenue and 63%-65% margins.
Apyx Medical Slides: Investor presentation
Apyx Medical has posted slides in relation to its latest quarterly earnings report, which was published on November 11, 2026.
Apyx Medical Transcript: UBS Global Healthcare Conference
AYON reached full Power Lipo release, while only ~15% of the Renuvion installed base had upgraded. Management sees GLP-1-driven surgical demand and international expansion as significant long-term opportunities.
Apyx Medical reports Q3 EPS (4c), consensus (9c)
Reports Q3 revenue $14.03M, consensus $13.29M. “We are pleased to report 17% growth in our Surgical Aesthetics business for the quarter, reflecting continued adoption of AYON and the progress we…
Apyx Medical backs FY26 revenue view $59M-$60M, consensus $59.41M
The company said, “The Company expects gross margins in the range of 63% to 65%. The Company now expects operating expenses in the range of $41.0 million to $42.5 million…
Apyx Medical Earnings Call Transcript: Q3 2026
Q3 revenue rose 9% YoY to $14.0M, with Surgical Aesthetics growth led by AYON. FY26 revenue guidance was reaffirmed, while the operating expense range was tightened.
Apyx Medical Earnings release: Q3 2026
Apyx Medical released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Apyx Medical Quarterly report: Q3 2026
Apyx Medical has published its Q3 2026 quarterly earnings report on November 5, 2026.
Apyx Medical Corporation Reports Third Quarter 2026 Financial Results
Reported total revenue of $14.0 million in the third quarter of 2026 driven by 17% growth in the Surgical Aesthetics segment Initiated successful full commercial launch of the power liposuction handpi...
Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
CLEARWATER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the A...
Apyx Medical Corporation to Participate in Upcoming Investor Conferences
CLEARWATER, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYO...
Apyx Medical announces study demonstrating Renuvio’s impact on skin quality
Apyx Medical (APYX) announced results from a prospective clinical study evaluating the effects of Renuvion helium plasma radiofrequency technology on biological markers of skin quality. The study was ...
Apyx Medical Announces New Clinical Study Demonstrating Renuvion®'s Impact on Skin Quality
CLEARWATER, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the ...
Apyx Medical initiated with a Buy at Maxim
Maxim initiated coverage of Apyx Medical (APYX) with a Buy rating and $6 price target
Apyx Medical Slides: Investor presentation
Apyx Medical has posted slides in relation to its latest quarterly earnings report, which was published on August 28, 2026.
Apyx Medical Transcript: Canaccord Genuity's 46th Annual Growth Conference
GLP-1 drugs are driving a new wave of demand for surgical aesthetics, especially skin tightening and body contouring. The AYON system, integrating multiple advanced technologies, is positioned for strong growth, with international expansion and profitability as key goals.
Apyx Medical reports Q2 EPS (7c), consensus (8c)
Reports Q2 revenue $13.88M, consensus $13.18M. “We are excited by the increasing demand for AYON throughout the U.S. market, which we believe reflects the successful execution of our commercial strate...
Apyx Medical backs FY26 revenue view $59M-$60M, consensus $59.55M
The company said, “The Company continues to expect operating expenses of less than $45.0 million for the year ended December 31, 2026.”
Apyx Medical Earnings Call Transcript: Q2 2026
Revenue grew 22% year-over-year to $13.9M, led by AYON platform adoption and strong surgical aesthetics sales. Gross margin improved to 63.9%, and net loss narrowed. Full-year guidance reaffirmed, with liquidity expected into 2028.
Apyx Medical Earnings release: Q2 2026
Apyx Medical released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Apyx Medical Quarterly report: Q2 2026
Apyx Medical has published its Q2 2026 quarterly earnings report on August 6, 2026.
Apyx Medical Corporation Reports Second Quarter 2026 Financial Results
CLEARWATER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYO...
Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference
CLEARWATER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the the leader in surgical aesthetics marketed and sold as Renuvion® and the...
Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
CLEARWATER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the A...
Apyx Medical initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Yi Chen initiated coverage of Apyx Medical (APYX) with a Buy rating and $7 price target Apyx is a commercial stage surgical aesthetics company developing advanced energy-based…